Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | ASCO 2026: personalized vaccines and triplet immunotherapy in melanoma

Omid Hamid • 30 May 2026
ASCO 2026
Melanoma Skin Cancer Antibodies Ipilimumab mRNA-4157 Nivolumab Relatlimab
KEYNOTE-942

Omid Hamid, MD, of The Angeles Clinic and Research Institute, discusses key advances in adjuvant and neoadjuvant melanoma treatment presented at ASCO 2026, including promising data from personalized cancer vaccine studies and triplet immunotherapy combinations incorporating CTLA-4, PD-1, and LAG-3 inhibition. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Omid Hamid

Advances in TIL therapy for melanoma and solid tumors highlighted at ASCO 2026
3:13
Advances in TIL therapy for melanoma and solid tumors highlighted at ASCO 2026
Omid Hamid • 30 May 2026
Melanoma immunotherapy strategies shape treatment approaches across solid tumors
0:55
Melanoma immunotherapy strategies shape treatment approaches across solid tumors
Omid Hamid • 30 May 2026
Prior CTLA-4 blockade linked to immunosuppressive signature in melanoma
2:05
Prior CTLA-4 blockade linked to immunosuppressive signature in melanoma
Omid Hamid • 30 May 2026
SYNERGY: nenocorilant and nivolumab in advanced solid malignancies
1:38
SYNERGY: nenocorilant and nivolumab in advanced solid malignancies
Omid Hamid • 30 May 2026

Related Videos

Advances in TIL therapy for melanoma and solid tumors highlighted at ASCO 2026
3:13
Advances in TIL therapy for melanoma and solid tumors highlighted at ASCO 2026
Omid Hamid • 30 May 2026
Melanoma immunotherapy strategies shape treatment approaches across solid tumors
0:55
Melanoma immunotherapy strategies shape treatment approaches across solid tumors
Omid Hamid • 30 May 2026
Predictors of toxicity and tolerability with lifileucel in advanced melanoma
1:18
Predictors of toxicity and tolerability with lifileucel in advanced melanoma
Alexandra Haugh • 30 May 2026
The Phase I/II trial of dendritic cell vaccine DOC1021 for refractory melanoma
1:00
The Phase I/II trial of dendritic cell vaccine DOC1021 for refractory melanoma
Alexandra Haugh • 30 May 2026
The content of VJOncology is intended for healthcare professionals